Phase 1Recruiting

AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

Sponsored by Amylyx Pharmaceuticals Inc.

About this study

This study is a placebo-controlled Phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide (ASO) AMX0114 in adult participants with amyotrophic lateral sclerosis (ALS).

Enrolling at this location

Alliance for Multispecialty Research, LLC

Knoxville, Tennessee

I'm interested

This study also enrolls at 9 other locations. See all.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.